Recon: Ono set to buy Deciphera for $2.4B; FDA approves X4’s ultra-rare immunodeficiency disease therapy

• Biden administration boosts some Medicaid payments to match commercial rates (STAT)
• House bill aimed at Chinese biotechs is advancing (STAT)
• Drugmaker AbbVie expects Humira volume erosion to worsen (Reuters)
• Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List (Pink Sheet)
• FDA’s Revised Draft Guidance on Biological Product Promotion Provides Additional Recommendations/Clarifications (FDA Law Blog)

• Doctors Without Borders challenges pharma by releasing costs for a key clinical trial (STAT)
• WuXi wants to regain client confidence amid claims of IP transfer to Chinese authorities (Endpoints)
• 4P-Pharma raises €15M; Oncotelic Therapeutics sells rights to cancer assets (Endpoints)
• MHRA Needs ‘Rebuilding’ After Post-Brexit Loss Of Capacity & Industry Investment (Pink Sheet)
• EU & South Korea Sign Deal On Exchange Of Confidential Information (Pink Sheet)
• EU Parliament OKs New Rules On Use Of Patient Data In Research (Pink Sheet)
• Merck KGaA, Huma collab bears fruit with launch of bladder cancer patient support app (Fierce Pharma)

• New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition (STAT)
• Ono Pharmaceutical to acquire Deciphera Pharma, maker of cancer drugs, for $2.4 billion (STAT)
• FDA approves X4 Pharmaceuticals' pill for ultra-rare immunodeficiency disease (Endpoints)
• AstraZeneca, Daiichi Sankyo’s Enhertu claims another Phase 3 victory in HER2-low breast cancer (Endpoints)
• Prime Medicine receives FDA clearance to run first prime editing clinical trial (Endpoints)
• Lead drug from J&J and Addex's 20-year collaboration flunks Phase 2 in epilepsy (Endpoints)
• Bristol Myers buys into Repertoire's autoimmune vaccines, giving new life to Flagship startup (Endpoints)
• Bristol Myers eyes major cuts; That $1B AI startup; Pharma reacts to China bill; Q1 earnings highlights; and more (Endpoints)
• UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs (Endpoints)
• US FDA approves Pfizer's gene therapy for rare bleeding disorder (Reuters)
• With sales still stagnant, BioMarin adds divestiture to list of options for gene therapy Roctavian (Fierce Pharma)

• Generative AI is supposed to save doctors from burnout. New data show it needs more training (STAT)
• Philips will pay $1.1 billion to resolve U.S. lawsuits over breathing machines that expel debris (STAT)
• Philips shares surge on US recall settlement news (Reuters)
• US FDA tightens scrutiny of lab-developed tests with new rule (Reuters)
• Livanova says patient data obtained in 2023 cyberattack (MedTech Dive)
• Fresenius Medical Care recalls 2M dialysis devices over toxin exposure risk (MedTech Dive)
• Edwards gets Q1 boost as Pascal valve repair sales ramp up (MedTech Dive)
• Infutronix infusion pump recall linked to 6 injuries, 1 death (MedTech Dive)

• AI is becoming the exclusive province of academic medicine. A new initiative aims to change that (STAT)
• Philip Morris faces key test with US heated tobacco push (Reuters)
• Ex-McKinsey partner sues firm, claims he was made opioids 'scapegoat' (Reuters)
• Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity (Pink Sheet)